Identifying and meeting the challenges of insulin therapy in type 2 diabetes

Journal of Multidisciplinary Healthcare

Volumn 7, Issue , 2014, Pages 267-282

  Sorli, Christopher ^a   Heile, Michael K ^b  

^a BILLINGS CLINIC   (United States)

^b The Family Medical Group Glenway   (United States)

Author keywords

Barriers; Emerging technologies; Individualized therapy; Insulin; Insulin analogs; Insulin pens; Patient education; Self management; Type 2 diabetes

Indexed keywords

BIOD 095; BIOD 105; BIOD 107; GLUCOSE; HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN DEGLUDEC; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; INSULIN PEGLISPRO; ISOPHANE INSULIN; SHORT ACTING INSULIN; UNCLASSIFIED DRUG;

COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DOCTOR PATIENT RELATION; DRUG ABSORPTION; DRUG DELIVERY DEVICE; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN INFUSION; INSULIN PEN DEVICE; INSULIN PUMP; INSULIN RESISTANCE; INSULIN TREATMENT; MEDICATION COMPLIANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT EDUCATION; PERSONALIZED MEDICINE; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; STEADY STATE; WEIGHT GAIN;

EID: 84903891254     PISSN: None     EISSN: 11782390     Source Type: Journal    
DOI: 10.2147/JMDH.S64084     Document Type: Review

References (137)

1. Heller S, Kozlovski P, Kurtzhals P. Insulin's 85th anniversary-An enduring medical miracle. Diabetes Res Clin Pract. 2007; 78(2): 149-158.
2. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999; 281(21): 2005-2012.
3. UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. UK Prospective Diabetes Study Group. Diabetes Care. 1998; 21(1): 87-92.
4. Weng J, Li Y, Xu W, etal. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet. 2008; 371(9626): 1753-1760.
5. Le Floch JP. Critical appraisal of the safety and efficacy of insulin detemir in glycemic control and cardiovascular risk management in diabetics. Diabetes Metab Syndr Obes. 2010; 3: 197-213.
6. Dailey G. New strategies for basal insulin treatment in type 2 diabetes mellitus. Clin Ther. 2004; 26(6): 889-901.
7. Garvey WT, Olefsky JM, Griffin J, Hamman RF, Kolterman OG. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes. 1985; 34(3): 222-234.
8. Robertson RP, Olson LK, Zhang HJ. Differentiating glucose toxicity from glucose desensitization: a new message from the insulin gene. Diabetes. 1994; 43(9): 1085-1089.
9. Wright A, Burden AC, Paisey RB, Cull CA, Holman RR; UK Prospective Diabetes Study Group. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57). Diabetes Care. 2002; 25(2): 330-336.
10. Skyler JS, Bergenstal R, Bonow RO, etal; American Diabetes Association; American College of Cardiology Foundation; American Heart Association. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol. 2009; 53(3): 298-304.
11. Gerstein HC, Bosch J, Dagenais GR, etal; ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012; 367(4): 319-328.
12. Mellbin LG, Rydén L, Riddle MC, etal; ORIGIN Trial Investigators. Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. Eur Heart J. 2013; 34(40): 3137-3144.
13. Inzucchi SE, Bergenstal RM, Buse JB, etal; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012; 35(6): 1364-1379.
14. American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care. 2014; 37 Suppl 1: S14-S80.
15. Ismail-Beigi F, Moghissi E, Tiktin M, Hirsch IB, Inzucchi SE, Genuth S. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med. 2011; 154(8): 554-559.
16. Cheung BM, Ong KL, Cherny SS, Sham PC, Tso AW, Lam KS. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med. 2009; 122(5): 443-453.
17. American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care. 2011; 34 Suppl 1: S11-S61.
18. Simonson GD, Cuddihy RM, Reader D, Bergenstal RM. International Diabetes Center Treatment of Type 2 Diabetes Glucose Algorithm. Diabetes Management. 2011; 1(2): 175-189.
19. Rodbard HW, Jellinger PS, Davidson JA, etal. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009; 15(6): 540-559.
20. Spann SJ, Nutting PA, Galliher JM, etal. Management of type 2 diabetes in the primary care setting: a practice-based research network study. Ann Fam Med. 2006; 4(1): 23-31.
21. Karter AJ, Subramanian U, Saha C, etal. Barriers to insulin initiation: the translating research into action for diabetes insulin starts project. Diabetes Care. 2010; 33(4): 733-735.
22. Peyrot M, Rubin RR, Kruger DF, Travis LB. Correlates of insulin injection omission. Diabetes Care. 2010; 33(2): 240-245.
23. Phillips LS, Branch WT, Cook CB, etal. Clinical inertia. Ann Intern Med. 2001; 135(9): 825-834.
24. el-Kebbi IM, Ziemer DC, Gallina DL, Dunbar V, Phillips LS. Diabetes in urban African-Americans. XV. Identification of barriers to provider adherence to management protocols. Diabetes Care. 1999; 22(10): 1617-1620.
25. Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care. 2004; 27(7): 1535-1540.
26. Cuddihy RM, Philis-Tsimikas A, Nazeri A. Type 2 diabetes care and insulin intensification: is a more multidisciplinary approach needed? Results from the MODIFY survey. Diabetes Educ. 2011; 37(1): 111-123.
27. Hayes RP, Fitzgerald JT, Jacober SJ. Primary care physician beliefs about insulin initiation in patients with type 2 diabetes. Int J Clin Pract. 2008; 62(6): 860-868.
28. LaSalle JR. Empowering patients during insulin initiation: a real-world approach. J Am Osteopath Assoc. 2010; 110(2): 69-78.
29. Brunton S, Gough S, Hicks D, etal. A look into the future: improving diabetes care by 2015. Curr Med Res Opin. 2011; 27 Suppl 3: 65-72.
30. American Diabetes Association. Standards of medical care in diabetes-2013. Diabetes Care. 2013; 36 Suppl 1: S11-S66.
31. Benroubi M. Fear, guilt feelings and misconceptions: barriers to effective insulin treatment in type 2 diabetes. Diabetes Res Clin Pract. 2011; 93 Suppl 1: S97-S99.
32. Cryer PE. Hypoglycemia in Diabetes: Pathophysiology, Prevalence, and Prevention. Alexandria, VA: American Diabetes Association; 2009.
33. Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care. 2005; 28(5): 1245-1249.
34. Brod M, Christensen T, Thomsen TL, Bushnell DM. The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health. 2011; 14(5): 665-671.
35. Miller CD, Phillips LS, Ziemer DC, Gallina DL, Cook CB, El-Kebbi IM. Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med. 2001; 161(13): 1653-1659.
36. Vexiau P, Mavros P, Krishnarajah G, Lyu R, Yin D. Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France. Diabetes Obes Metab. 2008; 10 Suppl 1: 16-24.
37. Pramming S, Thorsteinsson B, Bendtson I, Binder C. Symptomatic hypoglycaemia in 411 type 1 diabetic patients. Diabet Med. 1991; 8(3): 217-222.
38. Unger J, Parkin C. Hypoglycemia in insulin-treated diabetes: a case for increased vigilance. Postgrad Med. 2011; 123(4): 81-91.
39. Brunton SA. Nocturnal hypoglycemia: answering the challenge with long-acting insulin analogs. MedGenMed. 2007; 9(2): 38.
40. Allen KV, Frier BM. Nocturnal hypoglycemia: clinical manifestations and therapeutic strategies toward prevention. Endocr Pract. 2003; 9(6): 530-543.
41. Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003; 26(11): 3080-3086.
42. Rosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, Lin Z, Salzman A. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care. 2005; 28(4): 950-955.
43. Rosenstock J, Schwartz SL, Clark CM, Park GD, Donley DW, Edwards MB. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care. 2001; 24(4): 631-636.
44. Haak T, Tiengo A, Draeger E, Suntum M, Waldhäusl W. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab. 2005; 7(1): 56-64.
45. Little S, Shaw J, Home P. Hypoglycemia rates with basal insulin analogs. Diabetes Technol Ther. 2011; 13 Suppl 1: S53-S64.
46. Levin PA, Mersey JH, Zhou S, Bromberger LA. Clinical outcomes using long-term combination therapy with insulin glargine and exenatide in patients with type 2 diabetes mellitus. Endocr Pract. 2012; 18(1): 17-25.
47. Schappert SM, Rechtsteiner EA. Ambulatory medical care utilization estimates for 2007. Vital Health Stat. 2011; (169): 1-38.
48. Greaves CJ, Brown P, Terry RT, Eiser C, Lings P, Stead JW. Converting to insulin in primary care: an exploration of the needs of practice nurses. J Adv Nurs. 2003; 42(5): 487-496.
49. Frid A, Hirsch L, Gaspar R, et al; Scientific Advisory Board for the Third Injection Technique Workshop. New injection recommendations for patients with diabetes. Diabetes Metab. 2010; 36 Suppl 1: S3-S18.
50. Nakar S, Yitzhaki G, Rosenberg R, Vinker S. Transition to insulin in Type 2 diabetes: family physicians' misconception of patients' fears contributes to existing barriers. J Diabetes Complications. 2007; 21(4): 220-226.
51. Polonsky WH, Fisher L, Guzman S, Villa-Caballero L, Edelman SV. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care. 2005; 28(10): 2543-2545.
52. Meece J. Dispelling myths and removing barriers about insulin in type 2 diabetes. Diabetes Educ. 2006; 32(Suppl 1): 9S-18S.
53. Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic medication in a population of patients with Type 2 diabetes: a retrospective cohort study. Diabet Med. 2002; 19(4): 279-284.
54. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med. 2012; 29(5): 682-689.
55. Ratner R, Wynne A, Nakhle S, Brusco O, Vlajnic A, Rendell M. Influence of preprandial vs postprandial insulin glulisine on weight and glycaemic control in patients initiating basal-bolus regimen for type 2 diabetes: a multicenter, randomized, parallel, open-label study (NCT00135096). Diabetes Obes Metab. 2011; 13(12): 1142-1148.
56. Meneghini L, Mersebach H, Kumar S, Svendsen AL, Hermansen K. Comparison of 2 intensification regimens with rapid-acting insulin aspart in type 2 diabetes mellitus inadequately controlled by once-daily insulin detemir and oral antidiabetes drugs: the step-wise randomized study. Endocr Pract. 2011; 17(5): 727-736.
57. Raccah D, Haak T, Huet D, etal. Stepwise intensification of prandial insulin versus basal-bolus insulin therapy in patients with type 2 diabetes mellitus [abstract]. Diabetologia. 2010; 53(Suppl 1): S382.
58. Hirsch IB. Insulin analogues. N Engl J Med. 2005; 352(2): 174-183.
59. Vázquez-Carrera M, Silvestre JS. Insulin analogues in the management of diabetes. Methods Find Exp Clin Pharmacol. 2004; 26(6): 445-461.
60. Ulrich H, Snyder B, Garg SK. Combining insulins for optimal blood glucose control in type I and 2 diabetes: focus on insulin glulisine. Vasc Health Risk Manag. 2007; 3(3): 245-254.
61. Home PD, Lindholm A, Hylleberg B, Round P. Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group. Diabetes Care. 1998; 21(11): 1904-1909.
62. Anderson JH Jr, Brunelle RL, Koivisto VA, Trautmann ME, Vignati L, DiMarchi R. Improved mealtime treatment of diabetes mellitus using an insulin analogue. Multicenter Insulin Lispro Study Group. Clin Ther. 1997; 19(1): 62-72.
63. Hartman I. Insulin analogs: impact on treatment success, satisfaction, quality of life, and adherence. Clin Med Res. 2008; 6(2): 54-67.
64. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care. 2000; 23(5): 644-649.
65. Suzuki D, Toyoda M, Kondo M, etal. Efficacy of long-acting insulin analog insulin glargine at high dosage for basal-bolus therapy in patients with type 2 diabetes. Tokai J Exp Clin Med. 2012; 37(2): 35-40.
66. Raskin P, Gylvin T, Weng W, Chaykin L. Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes. Diabetes Metab Res Rev. 2009; 25(6): 542-548.
67. Plank J, Bodenlenz M, Sinner F, etal. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care. 2005; 28(5): 1107-1112.
68. Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab. 2007; 9(3): 290-299.
69. Lepore M, Pampanelli S, Fanelli C, etal. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000; 49(12): 2142-2148.
70. Meneghini L, Atkin SL, Bain S, etal. Flexible once-daily dosing of insulin degludec does not compromise glycemic control or safety compared to insulin glargine given once daily at the same time each day in people with type 2 diabetes. Diabetes. 2011; 60 Suppl 1: LB10-LB11.
71. Russell-Jones DL, Hollander P, Miranda-Palma B. Altering the time of day of once-daily dosing of insulin degludec achieves similar glycemic control and safety compared to dosing the same time of day in people with type 1 diabetes. Diabetes. 2012; 61 Suppl 1: A91.
72. Mathieu C, Hollander P, Miranda-Palma B, etal. Insulin degludec allows for flexible daily dosing in type 1 diabetes, providing equal glycemic control with less nocturnal hypoglycemia than insulin glargine over 52 weeks. Can J Diabetes. 2012; 36(5): S56-S57.
73. Hirsch L, Gibney M, Berube J, Manocchio J. Impact of a modified needle tip geometry on penetration force as well as acceptability, preference, and perceived pain in subjects with diabetes. J Diabetes Sci Technol. 2012; 6(2): 328-335.
74. Korytkowski M, Bell D, Jacobsen C, Suwannasari R; FlexPen Study Team. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther. 2003; 25(11): 2836-2848.
75. Flood T. Advances in insulin delivery systems and devices: beyond the vial and syringe. Insulin. 2006; 1(3): 99-108.
76. Cobble ME. Initiating and intensifying insulin therapy for type 2 diabetes: why, when, and how. Am J Ther. 2009; 16(1): 56-64.
77. Peyrot M, Rubin RR, Lauritzen T, etal; International DAWN Advisory Panel. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005; 28(11): 2673-2679.
78. Polonsky WH, Hajos TR, Dain MP, Snoek FJ. Are patients with type 2 diabetes reluctant to start insulin therapy? An examination of the scope and underpinnings of psychological insulin resistance in a large, international population. Curr Med Res Opin. 2011; 27(6): 1169-1174.
79. Marrero DG. Overcoming patient barriers to initiating insulin therapy in type 2 diabetes mellitus. Clin Cornerstone. 2007; 8(2): 33-40; discussion 41-43.
80. Cameron CG, Bennett HA. Cost-effectiveness of insulin analogues for diabetes mellitus. CMAJ. 2009; 180(4): 400-407.
81. Tunis SL, Minshall ME, Conner C, etal. Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis. Curr Med Res Opin. 2009; 25(5): 1273-1284.
82. Tunis SL, Sauriol L, Minshall ME. Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in Canada. Appl Health Econ Health Policy. 2010; 8(4): 267-280.
83. Bullano MF, Al-Zakwani IS, Fisher MD, Menditto L, Willey VJ. Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products. Curr Med Res Opin. 2005; 21(2): 291-298.
84. Borah BJ, Darkow T, Bouchard J, Aagren M, Forma F, Alemayehu B. A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetes. Clin Ther. 2009; 31(3): 623-631.
85. Charbonnel B, Penfornis A, Varroud-Vial M, Kusnik-Joinville O, Detournay B. Insulin therapy for diabetes mellitus: treatment regimens and associated costs. Diabetes Metab. 2012; 38(2): 156-163.
86. Gu Q, Zeng F, Patel BV, Tripoli LC. Part D coverage gap and adherence to diabetes medications. Am J Manag Care. 2010; 16(12): 911-918.
87. Bonafede MM, Kalsekar A, Pawaskar M, etal. Insulin use and persistence in patients with type 2 diabetes adding mealtime insulin to a basal regimen: a retrospective database analysis. BMC Endocr Disord. 2011; 11: 3.
88. Lee WC, Balu S, Cobden D, Joshi AV, Pashos CL. Copayment level and medication adherence in type 2 diabetes patients managed with insulin aspart pen therapy [abstract]. Value Health. 2007; 10: A63.
89. Aydin CM, Taylor R, Billington EO, Tildesley HD. Insulin therapy is no cheaper than thiazolidinedione therapy in patients with type 2 diabetes. BC Med J. 2006; 48(8): 392-398.
90. Meneghini L. Advances in insulin therapy: physiological replacement with insulin analogs. US Endocrinol. 2007; 1: 27-28.
91. Søndergaard LG, Stoltenberg M, Flyvbjerg A, etal. Zinc ions in beta-cells of obese, insulin-resistant, and type 2 diabetic rats traced by autometallography. APMIS. 2003; 111(12): 1147-1154.
92. Dailey G, Rosenstock J, Moses RG, Ways K. Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care. 2004; 27(10): 2363-2368.
93. Pala L, Mannucci E, Dicembrini I, Rotella CM. A comparison of mealtime insulin aspart and human insulin in combination with metformin in type 2 diabetes patients. Diabetes Res Clin Pract. 2007; 78(1): 132-135.
94. Heise T, Nosek L, Rønn BB, etal. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004; 53(6): 1614-1620.
95. Meneghini LF, Orozco-Beltran D, Khunti K, etal. Weight beneficial treatments for type 2 diabetes. J Clin Endocrinol Metab. 2011; 96(11): 3337-3353.
96. Yki-Järvinen H, Dressler A, Ziemen M; HOE 901/300s Study Group. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care. 2000; 23(8): 1130-1136.
97. Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care. 2006; 29(6): 1269-1274.
98. Heise T, Tack CJ, Cuddihy R, etal. A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial. Diabetes Care. 2011; 34(3): 669-674.
99. Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab. 2007; 9(5): 648-659.
100. Shanik MH. Intensifying insulin therapy with insulin analog premixes: transitioning from basal insulin in type 2 diabetes. Diabetes Technol Ther. 2012; 14(6): 533-539.
101. Boehm BO, Home PD, Behrend C, Kamp NM, Lindholm A. Premixed insulin aspart 30 vs premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients. Diabet Med. 2002; 19(5): 393-399.
102. Garber AJ. Premixed insulin analogues for the treatment of diabetes mellitus. Drugs. 2006; 66(1): 31-49.
103. Roach P, Yue L, Arora V. Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Humalog Mix25 Study Group. Diabetes Care. 1999; 22(8): 1258-1261.
104. Tibaldi JT. Biphasic insulin aspart 70/30 three times a day in older patients with type 2 diabetes not achieving optimal glycemic control on a twice-daily regimen: a retrospective case series analysis from clinical practice. Adv Ther. 2007; 24(6): 1348-1356.
105. Kilo C, Mezitis N, Jain R, Mersey J, McGill J, Raskin P. Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin. J Diabetes Complications. 2003; 17(6): 307-313.
106. Arnolds S, Kuglin B, Kapitza C, Heise T. How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes. Int J Clin Pract. 2010; 64(10): 1415-1424.
107. Jonassen I, Havelund S, Ribel U, etal. Insulin degludec: multi-hexamer formation is the underlying basis for this new generation ultra-long acting basal insulin. Diabetologia. 2010; 53(Suppl 1): S388.
108. Kurtzhals P, Heise T, Strauss HM, etal. Multi-hexamer formation is the underlying mechanism behind the ultra-long glucose-lowering effect of insulin degludec [abstract]. Diabetes. 2011; 60(Suppl 1A): LB12.
109. Garber AJ, King AB, Del Prato S, etal; NN1250-3582 (BEGIN BB T2D) Trial Investigators. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012; 379(9825): 1498-1507.
110. Niskanen L, Leiter LA, Franek E, etal. Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial. Eur J Endocrinol. 2012; 167(2): 287-294.
111. Krasner A, Pohl R, Simms P, Pichotta P, Hauser R, De Souza E. A review of a family of ultra-rapid-acting insulins: formulation development. J Diabetes Sci Technol. 2012; 6(4): 786-796.
112. Pohl R, Hauser R, Li M, etal. Ultra-rapid absorption of recombinant human insulin induced by zinc chelation and surface charge masking. J Diabetes Sci Technol. 2012; 6(4): 755-763.
113. Castle JR, Morrow L, Pitts A, etal. Evaluations of modified ultra-rapid acting Linjeta™ formulations BIOD-105 and BIOD-107 in patients with type 1 diabetes [abstract]. Diabetes. 2012; 61(Suppl 1): A91.
114. Bergenstal RM, Rosenstock J, Arakaki RF, etal. A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. Diabetes Care. 2012; 35(11): 2140-2147.
115. Anderson BJ, Redondo MJ. What can we learn from patient-reported outcomes of insulin pen devices? J Diabetes Sci Technol. 2011; 5(6): 1563-1571.
116. Goldstein HH. Pen devices to improve patient adherence with insulin therapy in type 2 diabetes. Postgrad Med. 2008; 120(3): 172-179.
117. Cobden D, Lee WC, Balu S, Joshi AV, Pashos CL. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus. Pharmacotherapy. 2007; 27(7): 948-962.
118. Lee WC, Balu S, Cobden D, Joshi AV, Pashos CL. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther. 2006; 28(10): 1712-1725; discussion 1710-1711.
119. Baser O, Bouchard J, DeLuzio T, Henk H, Aagren M. Assessment of adherence and healthcare costs of insulin device (FlexPen) versus conventional vial/syringe. Adv Ther. 2010; 27(2): 94-104.
120. Bode BW. Insulin pump use in type 2 diabetes. Diabetes Technol Ther. 2010; 12 Suppl 1: S17-S21.
121. White RD. Insulin pump therapy (continuous subcutaneous insulin infusion). Prim Care. 2007; 34(4): 845-871, vii.
122. Golden SH, Sapir T. Methods for insulin delivery and glucose monitoring in diabetes: summary of a comparative effectiveness review. J Manag Care Pharm. 2012; 18(Suppl 6): S1-S17.
123. Selam JL. Evolution of diabetes insulin delivery devices. J Diabetes Sci Technol. 2010; 4(3): 505-513.
124. Kumareswaran K, Thabit H, Leelarathna L, etal. Feasibility of closed-loop insulin delivery in type 2 diabetes: a randomised controlled study. Diabetes Care. 2014; 37(5): 1198-1203.
125. Beyazit E, Mollaoǧlu M. Investigation of effect on glycosylated hemoglobin, blood pressure, and body mass index of diabetes intensive education program in patients with type 2 diabetes mellitus. Am J Mens Health. 2011; 5(4): 351-357.
126. Blonde L, Merilainen M, Karwe V, Raskin P; TITRATE Study Group. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets-the TITRATE study. Diabetes Obes Metab. 2009; 11(6): 623-631.
127. Meneghini L, Koenen C, Weng W, Selam JL. The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes-results of the randomized, controlled PREDICTIVE 303 study. Diabetes Obes Metab. 2007; 9(6): 902-913.
128. Campbell RK, Martin TM. The chronic burden of diabetes. Am J Manag Care. 2009; 15(Suppl 9): S248-S254.
129. Meneghini L. Why and how to use insulin therapy earlier in the management of type 2 diabetes. South Med J. 2007; 100(2): 164-174.
130. American Association of Clinical Endocrinologists. American College of Endocrinology consensus statement on guidelines for glycemic control. Endocr Pract. 2002; 8(Suppl 1): 5-11.
131. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003; 26(3): 881-885.
132. Riddle M, Umpierrez G, DiGenio A, Zhou R, Rosenstock J. Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes. Diabetes Care. 2011; 34(12): 2508-2514.
133. Potti LG, Haines ST. Continuous subcutaneous insulin infusion therapy: A primer on insulin pumps. J Am Pharm Assoc (2003). 2009; 49(1): e1-e13.
134. Edelman SV, Bode BW, Bailey TS, etal. Insulin pump therapy in patients with type 2 diabetes safely improved glycemic control using a simple insulin dosing regimen. Diabetes Technol Ther. 2010; 12(8): 627-633.
135. Labrousse-Lhermine F, Cazals L, Ruidavets JB, Hanaire H; GEDEC Study Group. Long-term treatment combining continuous subcutaneous insulin infusion with oral hypoglycaemic agents is effective in type 2 diabetes. Diabetes Metab. 2007; 33(4): 253-260.
136. Parkner T, Laursen T, Vestergaard ET, etal. Insulin and glucose profiles during continuous subcutaneous insulin infusion compared with injection of a long-acting insulin in Type 2 diabetes. Diabet Med. 2008; 25(5): 585-591.
137. Selam JL, Koenen C, Weng W, Meneghini L. Improving glycemic control with insulin detemir using the 303 Algorithm in insulin naïve patients with type 2 diabetes: a subgroup analysis of the US PREDICTIVE 303 study. Curr Med Res Opin. 2008; 24(1): 11-20.